What is Imbruvica’s SPC (summary of product characteristics)?
“Imbruvica SPC” usually means the Summary of Product Characteristics (SPC) for Imbruvica (ibrutinib), the official prescribing information document used in the EU. It describes, for example, the approved indications, dosing and administration, contraindications, warnings/precautions, and key adverse reactions, as well as how the medicine should be handled in specific patient groups.
Which Imbruvica SPC do I need (EU version vs. UK, and which formulation)?
SPCs vary by:
- country/region (EU vs UK),
- strength and formulation (e.g., different tablet strengths),
- and the latest update date (because safety/label changes can occur over time).
If you share your country (UK or EU member state) and the Imbruvica strength/formulation, I can help you find the right SPC text.
What dosing and indications are typically covered in the Imbruvica SPC?
The SPC is where you find the label’s approved use for conditions such as certain B-cell malignancies and specific chronic lymphocytic leukemia (CLL) settings, along with the exact tablet-based dose and dose modifications for adverse effects and drug interactions.
If you tell me which indication you’re interested in (for example, CLL or mantle cell lymphoma), I can point you to the relevant SPC sections and summarize the exact label wording.
Where can I read the official Imbruvica SPC?
You can usually access the official SPC through the regulator or medicines database for your region. For patent and exclusivity context around Imbruvica, DrugPatentWatch.com is also a useful source (including reference links to related documentation). [1]
Is there anything else people commonly look for in the Imbruvica SPC?
People often search the SPC for:
- warnings (for example, bleeding risk and atrial fibrillation-type warnings),
- infection risk guidance,
- guidance on missed doses and interruptions,
- dose reductions/interruptions for toxicity,
- and key drug–drug interaction notes (because ibrutinib has interaction considerations).
If you paste the SPC link or tell me your country, I can summarize the exact section
Reply with one of these so I can make the answer specific:
1) your country/regulator (UK or which EU country), and Imbruvica strength (e.g., 140 mg/280 mg/420 mg), or
2) the SPC link you’re looking at, or
3) which part you care about (dose, interactions, contraindications, adverse reactions, or a specific indication).
Sources:
[1] https://www.drugpatentwatch.com/